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Abstract
Familial high-density lipoprotein (HDL)-deficiency syndromes are caused by mutations of the ABCA1 gene, coding for the
ATP-binding cassette transporter 1. We have developed a homogeneous assay based on 52 primer sets to amplify all
50 ABCA1 exons and approximately 1 kb of its promoter. The assay allows for convenient amplification of the gene from
genomic DNA and easy mutational analysis through automatic sequencing. It obviates the need to use mRNA preparations,
which were difficult to handle and posed a risk to miss splice junction or promoter mutations. The application of the test to
the molecular analysis of a new patient with familial HDL-deficiency (Tangier disease) led to a discovery of two novel
ABCA1 mutations: C2665del and C4457T. ß 2001 Published by Elsevier Science B.V.
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1. Introduction
The causative relationship between mutations in
the ABCA1 gene and familial high-density lipopro-
tein (HDL)-cholesterol de¢ciency syndromes was
found independently by us and two other groups
[1^3] and later con¢rmed by additional reports [4^
7]. Initially, using the method of di¡erential display,
we identi¢ed ABCA1 as cholesterol-regulated gene
that was upregulated by cholesterol loading and
downregulated by HDL-mediated lipid export in hu-
man macrophages [8]. In addition, ABCA1 was lo-
cated in the same region, 9q31, to where Tangier
disease (TD) was mapped [9]. Therefore, we consid-
ered ABCA1 a functional as well as a positional can-
didate for familial HDL-de¢ciency syndromes such
as TD.
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Classical TD patients have extremely low levels of
HDL-cholesterol (HDL-C), reduced levels of apoli-
poprotein A-I (apoA-I) and increased levels of trigly-
cerides. The storage of cholesteryl esters in reticulo-
endothelial system leads to splenomegaly and en-
largement of pharyngeal tonsils. Our investigation
of knock-out mice proved that abc1, the murine ho-
mologue of the human ABCA1, is expressed on the
plasma membrane and Golgi complex, mediates apo-
AI associated export of cholesterol and phospholip-
ids from the cell, and is regulated by cholesterol £ux
[10].
Although familial HDL-de¢ciency itself is very
rare, it may give clues to the general mechanisms
of HDL metabolism. In order to facilitate the search
for mutations and common polymorphisms in
Table 1
ABCA1 primer set for exon ampli¢cation
Exon Primer name Primer sequence Exon size (bp) Size of PCR product (bp)
prom1 AB-pro1-f ggaggtctggagtggctacata A 813 bp fragment of the promoter 554
AB-pro1-r ccagtggaatttgcttcctcta
prom2 AB-pro2-f agcccattacccagaggactgt 466
AB-pro2-r ttcagtcactcagcagaaagca
0 AB-ex0-f agcacaggctttgaccgatagt 221 395
AB-ex0-r ggatcaaagtccccgaaacc
1 AB-ex1-f tcctcattggtgtatggctttg 158 358
AB-ex1-r aagagccagattccatcaatcc
2 AB-ex2-f ccacgatgaatcctgaagaatg 94 540
AB-ex2-r ctcctgagttcatgccttatca
3 AB-ex3-f atcacttctccaacgctggtat 142 519
AB-ex3-r tgcagactctatcacacaagca
4 AB-ex4-f aggcagttggcctagctaaag 119 236
AB-ex4-r ctactctctttccctggtgcag
5 AB-ex5-f gcctatcatggtgaaaccctgt 122 297
AB-ex5-r tctttccagtagctgcacaacg
6 AB-ex6-f aaagacttcaaggacccagctt 177 321
AB-ex6-r cctcacattccgaaagcatta
7 AB-ex7-f tttggttaggagtcggtttcttg 93 456
AB-ex7-r gggctggtctgttagccacta
8 AB-ex8-f tctttctcttctcatccccaac 241 417
AB-ex8-r gctgctacagagggaggagat
9 AB-ex9-f tccaaagcccttgtaagtttct 140 305
AB-ex9-r tacttagcgcacacctctgaag
10 AB-ex10-f ctcattgtctgtgcttctcctc 117 240
AB-ex10-r gtgaccagaaactcacctctcc
11 AB-ex11-f tgctcctcaagatttagttggtg 198 306
AB-ex11-r tcagagaaagaagccgttaagtc
12 AB-ex12-f gatgagcaatcgtgtagtcagc 206 487
AB-ex12-r accttccagcaagtcatgtacc
13 AB-ex13-f gggcaataagagtgaaactcca 177 438
AB-ex13-r tttccagatcattcacacatgc
14 AB-ex14-f agagtctagagggcctgtcctt 223 593
AB-ex14-r gaaccctgcactctcatcctac
15 AB-ex15-f tacaagtgagtgcttgggattg 222 391
AB-ex15-r cccattggaaaagacaatcatc
16 AB-ex16-f ttctgcaccttatgattgatcc 205 392
AB-ex16-r agcacaaagaaaggacatcagc
17 AB-ex17-f cagaatactgggatgatgctga 114 227
AB-ex17-r aacagttagcagaggcagcag
18 AB-ex18-f tgtccttacactccactcctca 172 292
AB-ex18-r ctctactgcagaaccctcctgt
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Table 1 (continued)
Exon Primer name Primer sequence Exon size (bp) Size of PCR product (bp)
19 AB-ex19-f aagcagatgtgagaagcacctg 132 868
AB-ex19-r taagtcccactcctcccatgat
20 AB-ex20-f cgatctgtcacctttcactttg 143 490
AB-ex20-r gccagggacaagtttctgttac
21 AB-ex21-f ctctgccttcactcactgtctg 138 283
AB-ex21-r tagccatgagatacagccacac
22 AB-ex22-f tgtgacaaatcagaactgagagg 221 366
AB-ex22-r ggtggagatggagaaatcattc
23 AB-ex23-f cacacaacagagcttcttggaa 73 257
AB-ex23-r tctgcacctctcctcctctg
24 AB-ex24-f ggaatgacctaaacacctggaa 204 402
AB-ex24-r aggctactggtctggccttag
25 AB-ex25-f ggcttctctcccaggtaactct 49 404
AB-ex25-r gcacaaggaaagaatcccatac
26 AB-ex26-f tcagtgcacgagtattgttcct 114 400
AB-ex26-r tggcttttaccatttcctcact
27 AB-ex27-f ttcagacacatgccttcaagat 149 403
AB-ex27-r gcaaggaatagaactgggattg
28 AB-ex28-f ctcagtcttcaggaggaggaag 125 517
AB-ex28-r catctttggtctgctcgaatc
29 AB-ex29-f ttggagtgctctacgtcacc 99 402
AB-ex29-r gtcactaatgtggcatgcagtt
30 AB-ex30-f gtttgtggttgttacggaatga 190 390
AB-ex30-r aacagaccctcccaacatgata
31 AB-ex31-f tctgggacctgtagtcaggttt 95 412
AB-ex31-r ccttgaagctgacaactgaatg
32 AB-ex32-f tgcatcattaggaataggctca 33 401
AB-ex32-r cctgcaggagatttctgattct
33 AB-ex33-f gcagaaaccatgggagttaaga 106 380
AB-ex33-r tccgtttaacctgccaactact
34 AB-ex34-f gtccacaggttccagattgact 75 304
AB-ex34-r actacaccgtactgcctcactg
35 AB-ex35-f gttggtgggtatgcacctg 170 305
AB-ex35-r tctccataaccctctcccttg
36 AB-ex36-f actgattgagccctaactgcat 178 408
AB-ex36-r tgtgtttggtgtcatgaaagtg
37 AB-ex37-f gcttgactgttggaaagacaga 116 402
AB-ex37-r caccaaatgccttatccactg
38 AB-ex38-f acagtggataaggcatttggtg 145 400
AB-ex38-r agcaagaaagaaaggtgctttg
39 AB-ex39-f ttctcacttgcctagtggattg 124 860
AB-ex39-r atcctgtgcttagtcacctgct
40 AB-ex40-f cgaatacacattggctctgaaa 130 464
AB-ex40-r ttgagttcagttcaatgcaacc
41 AB-ex41-f ggagactgtggcaagtaggttt 121 442
AB-ex41-r tgtattcgagaatgggaattcat
42 AB-ex42-f gcctgtgttcaagagggtctat 63 565
AB-ex42-r cgttgcttgattgggtagaga
43 AB-ex43-f gtttgaggtagttacgtgttaggg 107 516
AB-ex43-r aactggattgtggtgatggttg
44 AB-ex44-f gcatgtgaatggtgcatatgag 142 567
AB-ex44-r gtcaggatgccaaaggagacag
45 AB-ex45-f cctcaccagttgtcaggttatg 135 512
AB-ex45-r agcctcaatcacgctaagaaac
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ABCA1 we developed a homogeneous assay based
on 52 primer sets to amplify all 50 exons and approx-
imately 1 kb fragment of the promoter.
2. Materials and methods
2.1. Development of polymerase chain reaction
(PCR) primers
In order to design appropriate PCR primers we
had ¢rst to establish intronic sequences £anking the
exons. We achieved this by sequencing with the use
of exonic primers. Based on the predicted size of the
intron, we either ampli¢ed the whole intron with
primers located in adjacent exons (Advantage Ge-
nomic PCR kit, Clontech Laboratories, Palo Alto,
USA) or performed genome walking experiments
(Human Genome Walker kit, Clontech). Subse-
quently, we used the newly obtained sequence infor-
mation to design a pair of PCR primers for each
exon. For the development of primer sets to amplify
the promoter region we used the published sequence
(Table 1).
Following DNA isolation from the whole blood
(Qiagen Blood and Cell Culture DNA Mini kit, Qia-
gen, Hilden, Germany) we ampli¢ed and sequenced
(ABI Prism Genetic Analyzer 310 PE Biosystems,
Foster City, USA) 52 genomic fragments of
ABCA1 in a new patient with familial HDL-de¢-
ciency syndrome and all three of his ¢rst-degree rel-
atives.
In order to prove a unique character of the novel
C4457T missense mutation we sequenced exon 31 in
50 healthy and unrelated control individuals (Ger-
man blood donors).
2.2. Patient description
The a¡ected individual, a 30-year-old man, was
brought to medical attention at the age of 25 years
because of splenomegaly and marked reduction of
HDL-cholesterol as well as ApoA-I and ApoA-II.
He had no detectable signs or symptoms of either
coronary artery disease or neuropathy. Although
both parents are obligate heterozygous carriers,
some reduction of HDL-cholesterol levels is only ap-
parent in the patient’s father. Subnormal levels of
HDL-cholesterol are also characteristic for the pa-
tient’s heterozygous sister (Fig. 1). However, the in-
terpretation of her lipid data is complicated due to
her excessive consumption of alcohol, which is re-
sponsible for hypertriglyceridemia (fasting: 328 mg/
dl; postprandial : 676 mg/dl), uric acidemia (5.9 mg/
dl; normal 6 5.6 mg/dl) and increased Q-glutamyl-
transferase levels (68 U/l; normal 6 18 U/l). The
medical assessment of the family revealed a history
of lupus erythematosus in the father since the age of
37 years, repeated ovary cysts and prominent varico-
sis in the mother and three miscarriages in the pa-
Table 1 (continued)
Exon Primer name Primer sequence Exon size (bp) Size of PCR product (bp)
46 AB-ex46-f gctgtttcaaagatgcttctgc 104 236
AB-ex46-r aaacatcccacagtgaggaac
47 AB-ex47-f agtcatggtgatgttctcatgg 93 309
AB-ex47-r ggacttcaaagccctcattctt
48 AB-ex48-f acttcatgggtccaggtgag 244 528
AB-ex48-r ggaatccacaccctgagaagta
49 AB-ex49-f cttccctccttcacacacagtt 141 500
AB-ex49-r gacataggctacaaaggcactg
List of 52 primer pairs for ampli¢cation of all 50 ABCA1 exons and approximately 1 kb promoter region immediately preceding the
transcription start site. All PCRs were optimized for the use with Qiagen Core kit (standard content and volume recommended by the
manufacturer, with Q-solution and no extra magnesium chloride). Cycling uses homogeneous conditions: initial denaturing at 95‡C
for 3 min; 35 cycles of denaturing at 95‡C for 45 s, annealing at 59‡C for 30 s and extension at 72‡C for 1 min; and ¢nal extension
at 72‡C for 10 min. All amplicons can be sequenced in either forward or reverse direction with the exception of fragments containing
exons 5, 13 and 36. These exons are £anked on their 5P-ends by highly polymorphic single nucleotide repeats, which complicate se-
quencing with forward primers located before repetitive regions. Exon numbering is based on initial reports which missed the 5P ex-
treme exon, referred to by us as exon 0.
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tient’s sister. However, there was no apparent evi-
dence for premature coronary artery disease.
3. Results
In order to be able to analyze individuals for mu-
tations or polymorphisms in the ABCA1 gene from
genomic DNA we have determined intronic sequen-
ces and designed primers therein for exon ampli¢ca-
tion. The 52 primer pairs and conditions for PCR
have been optimized in such a way that they can
amplify at a common annealing temperature (59‡C)
(Table 1). The amplicons can be sequenced in both
orientations except exons 5, 13 and 36 in which, be-
cause of highly polymorphic single nucleotide repeats
at their 5P-ends, the reverse primers should be used.
Using these primer pairs we found two monoallelic
di¡erences from the consensus sequence in the af-
fected patient. In exon 18 there was a deletion of a
single cytosine in nucleotide position 2665
(C2665del), the ¢rst nucleotide of codon 849, which
created a frameshift and premature ‘TGA’ termina-
tion signal four codons downstream from the muta-
tion site. In addition, the patient had a single nucle-
otide substitution in exon 31, which changed cytosine
in position 4457 to thymine (C4457T). This mutation
altered the sense of codon 1446, replacing a wild-type
serine with mutant leucine (S1446L). Molecular anal-
ysis of the patient’s parents proved that the identi¢ed
mutations were located on separate alleles since both
parents had only one mutation each: the mother
carried the missense substitution in exon 31, while
the father had a single nucleotide deletion in exon
18. Therefore, the two mutations detected in the pro-
band were transmitted separately on di¡erent alleles,
one of which was inherited from the mother and the
other from the father. Results of the ABCA1 se-
quence analysis in the patient’s sister were consistent
with heterozygosity for the mutation in exon 31. She
inherited this mutation from the mother but her oth-
er paternal allele was normal. Thus, it was only the
TD patient who had both mutant alleles.
4. Discussion
We developed a complete and homogeneous set of
52 primer pairs which allow for an e¡ective muta-
tional analysis of ABCA1. It is rather unusual that a
full list of optimized primers and PCR conditions is
made available for a gene which consists of as many
as 50 exons and spans some 6.5 kb of the coding
sequence. A common approach to molecular analysis
of such long genes is to sequence speci¢c reverse
transcription^PCR products. The major setback of
this strategy is the need to obtain and handle unsta-
ble mRNA and analyze amplicons representing
mRNA sequence, which poses a risk to miss splice
junction or promoter mutations. All these disadvan-
tages are eliminated in the presented assay, which
uses genomic DNA as a starting material. In addi-
tion, all primer pairs are optimized to work e⁄-
ciently in the same PCR conditions. Although a col-
lection of genomic primers for the ampli¢cation of
ABCA1 was previously reported by another group
[11], those authors failed to establish borders of sev-
eral exons in the 5P portion of the gene and, conse-
quently, they were unable to develop a complete set
of primer pairs. In contrast, our assay allows for the
ampli¢cation of all ABCA1 exons plus a 1 kb frag-
ment of the promoter.
The assay proved useful in the genetic analysis of
ABCA1 in a family with HDL-de¢ciency syndrome
Fig. 1. The four-member pedigree of the HDL-de¢ciency fam-
ily. The a¡ected individual is indicated by an arrow. Lipid val-
ues and distribution of the mutant and wild-type ABCA1 alleles
are incorporated in the ¢gure. All lipid values are in mg/dl.
Chol, total cholesterol.
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and we believe it may considerably facilitate the
search for new mutations and polymorphisms in
this important gene in populations of patients with
diminished HDL levels.
Two novel mutations found in the presented fam-
ily increase the spectrum of known molecular defects
of ABCA1. Predicted consequences of those muta-
tions support the notion of their deleterious impact
on the protein function. The deletion in exon 18
results in a frameshift and creation of a premature
stop codon, which would lead to early translation
termination and synthesis of defective polypeptide,
devoid of almost two thirds of its normal amino
acid sequence, including both ATP-binding cassettes.
The missense substitution in exon 31 changes a con-
served amino acid in the large extracellular loop fol-
lowing the ¢rst intracellular cassette. This loop has
most probably an important role for extracellular
interactions of ABCA1. The sequence comparison
of the ABCA1 and ABCA4 (also known as
ABCR), which is another representative of the
same subfamily A of ABC transporters, shows that
ABCA1 serine in position 1446 is analogous to
ABCA4 serine in position 1531 in a stretch of 11
amino acids, ten of which are conserved in both pro-
teins. The conserved amino acid residue of aspartic
acid in position 1532, immediately following the ser-
ine, was found mutated to asparagine in ABCA4 in a
patient with Stargardt disease, which proves an im-
portant functional role of this extracellular domain
in ABCs and suggests that mutation of serine in po-
sition 1446 in ABCA1 may have similarly deleterious
consequences.
The causative nature of this novel mutation is fur-
ther supported by the fact that we did not ¢nd it in
any of 50 healthy and unrelated blood donors (i.e.,
100 normal control chromosomes). Therefore, it is
highly unlikely that it is just an uncommon polymor-
phism exerting little or no impact on the protein
function.
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